Nimbus Therapeutics enters into strategic partnership with Charles River Laboratories to advance new therapeutic programs
Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL)…
Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL) launched a multi-year strategic partnership to advance new programs spanning the disease areas of immunology, metabolic disorders and oncology from the discovery phase through to Investigational New Drug (IND) submission.